Multidisciplinary care that includes growth hormone treatment should not cease once patients with Prader-Willi syndrome reach adulthood, according to authors of a study on care outcomes. There is a ...

Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

A Prescription Drug User Fee Act target date of December 27, 2024 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

With sleep apnea and abnormal sleep patterns typifying Prader-Willi syndrome, researchers from Sweden and Denmark theorized that treatment with growth hormone may improve both for individuals affected ...

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

REDWOOD CITY, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

How Does It Work for Excessive Hunger? Prader-Willi syndrome is a rare condition usually caused by genetic changes in your DNA. It can also occur after a head or brain injury. The condition affects ...

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray (ACP ...

Foundation Announces $60K Scholarship Fund with Miami Dade College to Expand Opportunities for Young Adults with Disabilities as They Transition to Adulthood The Supreme Twins Foundation – a nonprofit ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...

REDWOOD CITY, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, ...